Theriva Biologics, Inc. cotiza a 0.22 USD y tiene una capitalización bursátil de $10M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAG…
| Periodo | 2026-05 | 2025-11 | 2025-08 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.05 | $-0.45 | — | $-1.93 |
| Estimado | $-0.05 | $-0.38 | $-0.47 | $-0.47 |
| Sorpresa | +0.0% | -18.4% | — | -310.6% |
| Métrica | TOVX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -164.1% | -40.4% | -123.7% |
| ROA | -66.0% | -32.0% | -34.0% |
| Current Ratio | 1.74 | 2.84 | -1.10 |
| Debt / Equity | 0.11 | 0.28 | -0.17 |